Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $3.6 million.

  • Anika Therapeutics' Change in Accured Expenses rose 6409.09% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 2880.0%. This contributed to the annual value of -$3.7 million for FY2024, which is 32263.35% down from last year.
  • As of Q3 2025, Anika Therapeutics' Change in Accured Expenses stood at $3.6 million, which was up 6409.09% from -$2.2 million recorded in Q2 2025.
  • Anika Therapeutics' Change in Accured Expenses' 5-year high stood at $4.6 million during Q3 2023, with a 5-year trough of -$4.3 million in Q2 2023.
  • Over the past 5 years, Anika Therapeutics' median Change in Accured Expenses value was $406000.0 (recorded in 2021), while the average stood at -$31315.8.
  • In the last 5 years, Anika Therapeutics' Change in Accured Expenses surged by 28722.4% in 2021 and then plummeted by 56766.92% in 2024.
  • Anika Therapeutics' Change in Accured Expenses (Quarter) stood at $406000.0 in 2021, then tumbled by 237.44% to -$558000.0 in 2022, then soared by 231.54% to $734000.0 in 2023, then crashed by 227.38% to -$935000.0 in 2024, then soared by 486.1% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, -$2.2 million for Q2 2025, and -$3.1 million during Q1 2025.